Ardelyx
Biotechnology, Ardenwood BLVD Ste 200, Waltham, , 94555, Massachusetts, 34175, United States, 51-200 Employees
Phone Number: 51********
Who is ARDELYX
Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medic...
Read More
-
Headquarters: 34175 Ardenwood BLVD Ste 200, Waltham, Massachusetts, 94555, United States
-
Date Founded: 2007
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 32 |
Show More
Ardelyx Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Ardelyx
Answer: Ardelyx's headquarters are located at Ardenwood BLVD Ste 200, Waltham, , 94555, Massachusetts, 34175, United States
Answer: Ardelyx's phone number is 51********
Answer: Ardelyx's official website is https://ardelyx.com
Answer: Ardelyx's revenue is $1 Million to $5 Million
Answer: Ardelyx's SIC: 2834
Answer: Ardelyx's NAICS: 32
Answer: Ardelyx has 51-200 employees
Answer: Ardelyx is in Biotechnology
Answer: Ardelyx contact info: Phone number: 51******** Website: https://ardelyx.com
Answer: Ardelyx is a publicly traded biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyxs first approved product, IBSRELA (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis who have had an inadequate response or intolerance to phosphate binder therapy, which has completed three successful Phase 3 trials and an additional two Phase 4 open label trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month